601 GENOME WAY, HUNTSVILLE, AL
Financial Results, Press Release
Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s Disease
Receives NYSE Deficiency Notification Regarding Shareholders' Equity
Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Election of Directors at Serina Therapeutics' 2025 Annual Meeting
Provides Regulatory Update on SER-252 Program
Amended Annual Report
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Contested Proxy Solicitation Materials
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Correspondence
Submission Upload